Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

4 results
Display

Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report

Lim YH, Lee YY, Kim JH, Shin J, Lee JU, Kim KS, Kim SK, Kim JH, Lim HK

Essential thrombocythemia (ET) is a chronic myeloproliferative disorder with a prolonged clinical course. Since this disorder is considered to be at increased risk of thromboembolism, therapy is mainly focused on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cilostazol Reduces PAC-1 Expression on Platelets in Ischemic Stroke

Lee SY, Kang MJ, Cha JK

BACKGROUND AND PURPOSE: Cilostazol, a phosphodiesterase III inhibitor, is known to be a useful antiplatelet agent that inhibits the progression of atherosclerosis in ischemic stroke. This study investigated the effects...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Does Milrinone Improve Hemodynamic Variables in Patients with Pulmonary Hypertension Due to Valvular Heart Disease?

Shim YH, Oh YJ, Nam SB, Kim E, Hong YW, Kwak YL

BACKGROUND: Milrinone is a bipyridine phosphodiesterase III inhibitor that exerts both positive inotropic and direct vasodilatory effects. The efficacy and safety of intravenous milrinone in heart failure has been evaluated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Effects of Additional Cilostazol Administration After Drug-Eluting Stent Insertion

Kum DS, Kim MH, Paik JH, Yu LH, Han J, Kim KH, Park TH, Cha KS, Kim YD, Quan ML, Han JY

BACKGROUND AND OBJECTIVES: Cilostazol, a selective inhibitor of phosphodiesterase III (PDE III), prevents inactivation of the intracellular second messenger cyclic adenosine monophosphate (cAMP) and irreversibly inhibits platelet aggregation and vasodilation....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr